NYSE:DLB - Dolby Laboratories Stock Price, News, Headlines & Rumors

Dolby Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "DLB."

Dolby Laboratories declared a quarterly dividend on Thursday, July 26th. Shareholders of record on Monday, August 6th will be given a dividend of $0.16 per share on Tuesday, August 14th. This represents a $0.64 annualized dividend and a dividend yield of 0.95%. The ex-dividend date is Friday, August 3rd. View Dolby Laboratories' Dividend History.

Dolby Laboratories declared that its Board of Directors has approved a share buyback program on Sunday, April 9th 2017, which permits the company to repurchase $200,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 3.9% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board believes its shares are undervalued.

Dolby Laboratories, Inc. (NYSE:DLB) announced its earnings results on Wednesday, July, 25th. The electronics maker reported $0.92 EPS for the quarter, topping the consensus estimate of $0.69 by $0.23. The electronics maker had revenue of $317.45 million for the quarter, compared to analyst estimates of $317.65 million. Dolby Laboratories had a net margin of 8.18% and a return on equity of 12.95%. Dolby Laboratories's quarterly revenue was up 3.9% on a year-over-year basis. During the same period last year, the business posted $0.73 earnings per share. View Dolby Laboratories' Earnings History.

Dolby Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, October, 24th 2018. View Earnings Estimates for Dolby Laboratories.

Dolby Laboratories issued an update on its fourth quarter earnings guidance on Wednesday, July, 25th. The company provided earnings per share (EPS) guidance of $0.40-0.46 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.43. The company issued revenue guidance of $265-275 million, compared to the consensus revenue estimate of $271.27 million.

5 brokers have issued 12 month price targets for Dolby Laboratories' shares. Their predictions range from $52.00 to $78.00. On average, they expect Dolby Laboratories' share price to reach $66.40 in the next year. This suggests that the stock has a possible downside of 1.9%. View Analyst Price Targets for Dolby Laboratories.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dolby Laboratories in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dolby Laboratories.

Some companies that are related to Dolby Laboratories include InterDigital (IDCC), TiVo (TIVO), RPX (RPXC), Acacia Research (ACTG), Quarterhill (QTRH), Joint (JYNT), Digital Turbine (APPS), Liberty Tax (TAX), Finjan (FNJN), ITUS (ITUS), MGT Capital Investments (MGTI), XCel Brands (XELB), Research Frontiers (REFR), Marathon Patent Group (MARA) and ARC Group (ARCK).

News headlines about DLB stock have trended positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dolby Laboratories earned a coverage optimism score of 0.26 on Accern's scale. They also assigned media coverage about the electronics maker an impact score of 46.40 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Dolby Laboratories.

Dolby Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional investors include DOLBY DAGMAR (41.00%), DOLBY DAGMAR (40.60%), Janus Henderson Group PLC (3.65%), BlackRock Inc. (2.50%), FMR LLC (2.38%) and Renaissance Technologies LLC (2.16%). Company insiders that own Dolby Laboratories stock include Bob Borchers, Dagmar Dolby, Giles Baker, Kevin J Yeaman, Lewis Chew, Mark Andrew Sherman, Michael Bergeron, N William Jasper, Jr, Nicholas Donatiello Jr, Nicholas Donatiello, Jr, Peter C Gotcher and Steven E Forshay. View Institutional Ownership Trends for Dolby Laboratories.

DLB stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., American Century Companies Inc., Quantum Capital Management, Baillie Gifford & Co., Renaissance Technologies LLC, River Road Asset Management LLC, Burney Co. and Fuller & Thaler Asset Management Inc.. Company insiders that have sold Dolby Laboratories company stock in the last year include Bob Borchers, Dagmar Dolby, Giles Baker, Kevin J Yeaman, Lewis Chew, Mark Andrew Sherman, N William Jasper, Jr, Nicholas Donatiello Jr, Peter C Gotcher and Steven E Forshay. View Insider Buying and Selling for Dolby Laboratories.

DLB stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, FMR LLC, Bank of Montreal Can, Nantahala Capital Management LLC, Bradley Foster & Sargent Inc. CT, Wells Fargo & Company MN, Sumitomo Mitsui Asset Management Company LTD and Canada Pension Plan Investment Board. View Insider Buying and Selling for Dolby Laboratories.

Shares of DLB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DLB stock can currently be purchased for approximately $67.68.

Dolby Laboratories has a market capitalization of $6.83 billion and generates $1.08 billion in revenue each year. The electronics maker earns $201.80 million in net income (profit) each year or $2.20 on an earnings per share basis. Dolby Laboratories employs 2,122 workers across the globe.

Dolby Laboratories' mailing address is 1275 MARKET STREET, SAN FRANCISCO CA, 94103. The electronics maker can be reached via phone at 415-558-0200 or via email at [email protected]